SCHEMBL4125617

SCHEMBL4125617

Cc1cc(C(=C2SC(Nc3nc(CC(=O)O)cs3)=NC2=O)c2ccccc2)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.46
MAPT P10636 3/20 0.46
SCD O00767 6/20 0.41
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
ITGB1 P05556 2/20 0.37
ITGA4 P13612 2/20 0.37
PDE5A O76074 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE1C Q14123 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143528 0.82 FFAR1 (0.39) TP53
SCHEMBL4128243 0.66 GAA (0.45) GAAMAPTSCDALDH1A1NPC1
SCHEMBL4128240 0.66 GAA (0.45) GAAMAPTSCDALDH1A1NPC1
SCHEMBL4125618 0.66 MAPT (0.46) GAAMAPTSCDALDH1A1NPC1
SCHEMBL4125610 0.66 MAPT (0.46) GAAMAPTSCDALDH1A1NPC1
SCHEMBL4127740 0.64 PTP4A3 (0.48) GAAMAPTALDH1A1NPC1RAB9A
SCHEMBL4127746 0.64 PTP4A3 (0.48) GAAMAPTALDH1A1NPC1RAB9A
SCHEMBL27599948 0.64 KDM4E (0.78) SCDALDH1A1NPC1RAB9APDE5A
SCHEMBL12050107 0.63 MAPT (0.74) GAAMAPTALDH1A1NPC1RAB9A
SCHEMBL14069932 0.62 MAPT (0.68) GAAMAPTALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ GAA 387/4885MAPT 3532/4885SCD 4024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.